Diabetes Metab J.  2019 Dec;43(6):913-914. 10.4093/dmj.2019.0149.

Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)

• Kong SH
• Koo BK
• Moon MK

• KMID: 2466514
• DOI: http://doi.org/10.4093/dmj.2019.0149

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus, Type 2*
Humans

Reference

1. Kong SH, Koo BK, Moon MK. Effects of dapagliflozin on endothelial function, renal injury markers, and glycemic control in drug-naïve patients with type 2 diabetes mellitus. Diabetes Metab J. 2019; 43:711–717.

2. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001; 12:383–389.

3. Funk SD, Yurdagul A Jr, Orr AW. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med. 2012; 2012:569654.

4. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K1, Yoshida A, Jinnouchi K, Nishimura H, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med. 2018; 57:2147–2156.

5. Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017; 16:84.